



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents Washington, DC 20231" on

1644
Attorney Docket No. 9950-0002
PATENT

RECEIVED
OCT 12 2001
TECH CENTER 1600/2900

10/5/01
Date

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
ULRICH et. al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: M. Dibrino

International Application No.: PCT/EP98/02138

International Filing Date: April 3, 1998

Title: ALLERGEN FORMULATION

AMENDMENT UNDER 37 CFR § 1.111

Commissioner for Patents
Washington, DC 20231

Sir:

Submitted herewith for the subject application is and Amendment in response to the Office Action dated July 7, 2001, along with copies of references to which are referred in the Amendment.

No additional amendment fee is required.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-0580. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,

10/5/01
Date

By:

Dianne E. Reed
Registration No. 31,292

REED & ASSOCIATES
800 Menlo Avenue, Suite 210
Menlo Park, California 94025
(650) 330-0900 Telephone
(650) 330-0980 Facsimile



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Washington, D.C. 20231" on

Attorney Docket No. 9950-0002
Serial No. 09/402,273

Date:

October 5, 2001

Signature:

[Handwritten signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
ULRICH et al.

U.S. Serial No.: 09/402,273

Group Art Unit: 1644

U.S. Filing Date: December 13, 1999

Examiner: M. Dibrino

International Application No.: PCT/EP98/02138

International Filing Date: 03 April 1998

Title: ALLERGEN FORMULATION

1dA
KD
10-A-01

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in response to the Office Action in the above-identified case, mailed on July 7, 2001. Reconsideration of the application in view of the following remarks and amendments is respectfully requested.

AMENDMENTS

IN THE CLAIMS:

Please cancel claims 3 and 9-14 without prejudice.

Please amend claim 1 as indicated in Appendix A. The amended claim reads as follows:

1. (Amended) A pharmaceutical composition capable of selectively enhancing TH₁ response comprising tyrosine, an optionally modified allergen or allergen extract, and 3-DMPL.

A1